« Back to news listing

Endo Seen Boosted by Fidelity-Favored Sale: Real M&A

This article states “Endo Health Solutions Inc.’s best hope at regaining investor confidence after losing more than $1 billion in market value is to undo the acquisitions that built the company or find a buyer.”
Chief Executive Officer David Holveck is retiring two years after bolting a medical-device business onto his pain-treatment operations. Instead of the “ideal strategic fit” he promised, the stock lost 27 percent since Holveck agreed to pay almost $3 billion for American Medical Systems Holdings Inc., leaving Endo with the lowest valuation in the U.S. specialty pharmaceuticals industry, according to data compiled by Bloomberg.

Read entire article: http://www.bloomberg.com/news/2013-02-11/endo-seen-boosted-by-fidelity-favored-sale-real-m-a.html

« Back to news listing